Other cancer types with known HER2 expression include colorectal cancer, ovarian cancer, bladder cancer, and pancreatic cancer, and clinical trials with HER2-targeted compounds are expected to evaluate the targetability of HER2 alterations independent of primary indication in a tissue-agnostic way [66,67,68]. This evidence concerns the gene ERBB2 and ovarian cancer.